We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blocking Fatty Acid Synthesis Kills Some Forms of Brain Cancer

By LabMedica International staff writers
Posted on 29 Dec 2009
A possible therapeutic approach to treat rapidly growing tumors is to inhibit the synthesis of the fatty acids they require for formation of new membranes and as an alternative energy source.

Investigators at the University of California, Los Angeles (USA) worked with the most common form of brain cancer, glioblastoma. More...
This is one of the most difficult to treat cancers with the median survival for patients of from only 12 to 18 months.

The investigators focused their attention on the master regulator of fatty acid synthesis, sterol regulatory element-binding protein 1 (SREBP-1), which is in turn controlled by signaling from the epidermal growth factor receptor (EGFR). Although nearly 50% of glioblastomas develop because of overexpressed or mutant EGFR, clinical trials testing EGFR inhibitors have not been particularly successful, with only about 10 to 15% of patients responding.

In the current study, the investigators used genetic and pharmacologic approaches to identify the signaling pathways that EGFR uses to activate SREBP-1. They reported in the December 15, 2009, issue of the journal Science Signaling that glioblastomas with overexpressed or mutant EGFR were more dependent on fatty acid synthesis than cancers lacking these characteristics. Breaking the link between EGFR and SREBP-1 in these tumors caused the cancer cells to self-destruct.

"This suggests an important link between cancer progression and fatty acid synthesis and has raised the idea that targeting fatty acid synthesis could be an effective way to block cancer growth," said senior author Dr. Paul Mischel, professor of pathology and laboratory medicine at the University of California, Los Angeles.

"We found that EGFR signaling does activate the master regulator SREBP-1 to increase the amount of fatty acids in the cells," said Dr. Mischel. "We also were able to uncover the molecular circuitry linking EGFR with increased fatty acid synthesis. This is exciting because it identified a previously undescribed EGFR-controlled metabolic pathway and suggests new treatment approaches for EGFR-activated glioblastomas and perhaps other cancers with amplified signaling. We hope that interrupting fatty acid synthesis will kill tumor cells and spare the normal cells, decreasing treatment side effects."

Related Links:
University of California, Los Angeles




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette Calibration System
Artel PCS®
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.